Raymond Osarogiagbon, MBBS, FACP
@ROsarogiagbon
Director of the Multidisciplinary Thoracic Oncology Program and the Thoracic Oncology Research (ThOR) Group at the Baptist Cancer Center, in Memphis, TN
ID:1370422968845762562
12-03-2021 17:14:39
74 Tweets
354 Followers
70 Following
•Thrilled to be speaking at Mass General Cancer Center’s 2023 #CancerEquityColloquium in April! All are welcome to join this hybrid event in Boston as we tackle the diverse issues that underlie #cancerinequities . Learn more & save your seat: bit.ly/3iWzTN6 Mass General Brigham Professional Development
Now enrolling: SWOG Cancer Research Network S1934 #NASSIST trial: Neoadjuvant chemoradiation +/- #immunotherapy before surgery for superior sulcus non-small cell lung cancer. SWOG.org/clinical-trial…. PI: Raymond Osarogiagbon, MBBS, FACP #lungcancer #LCSM #NSCLC
What refinements should be made to the next edition of the TNM #lungcancer staging system? A session at #ELCC22 tackled this topic. Read a recap in ILCN: bit.ly/38nbpal Raymond Osarogiagbon, MBBS, FACP Ramon Rami Porta ESMO - Eur. Oncology #LCSM
Being in the center of the lung cancer mortality belt of America, we are striving to narrow this gap by 25% in the next 10 years & eliminate the stigma of lung cancer in the Mid-South. Find out more about the Mid-South Miracle on the Right Care podcast. player.captivate.fm/episode/6cf246…
Study led by Raymond Osarogiagbon, MBBS, FACP at Baptist Health Cancer Center highlights the need for incidental detection of lung nodules. USPSTF #LDCT guidelines are a great start but only a start. #lungcancer Qure.ai
ascopubs.org/doi/10.1200/JC…
#PLCClive22 Dr. Raymond Osarogiagbon, MBBS, FACP shows the significant state variation in low-dose CT screening for lung cancer. The rates are the lowest in areas where the need is the greatest (outlier is Kentucky where rates are very high). #HealthCareDisparities #LCSM
News: US research finds low rates of use of some standard therapies for resectable, early non-small-cell lung cancer. Read more about the study by Kenneth Kehl of Dana-Farber, Dr. Shakun Malik Suresh S. Ramalingam, MD, FASCO Raymond Osarogiagbon, MBBS, FACP & colleagues in JAMA Oncology #lcsm bit.ly/3txsRAA
Examining Geographic, Socioeconomic, and Racial Disparities in Lung Cancer Prevention and Care Raymond Osarogiagbon, MBBS, FACP Baptist Health #lcsm #oncology ow.ly/N5Nz50I2KPN
Join the panel discussion on #TTLC22 's Session on Therapy for Early Stage with donington Angel Qin U-M Rogel Cancer Center, Vincent Lam of Johns Hopkins Kimmel Cancer Center, Edgardo S. Santos, M.D., FACP, FASCO of Florida Precision Oncology R&C, Raymond Osarogiagbon, MBBS, FACP of Wake Forest Baptist - Comprehensive Cancer Center, Dr. Sanja Dacic of UPMC and nasser altorki of Weill Cornell Medicine
What can be done to optimize #lungcancer screening programs? Revisit research findings from #WCLC21 :bit.ly/3JeuF6B Mary Pasquinelli Raymond Osarogiagbon, MBBS, FACP #LCSM
#ClinicalTrials help broaden access to cancer care, offering people options that did not exist 50 years ago. “That's exciting, but none of it has any value,” said Dr. Raymond Osarogiagbon, MBBS, FACP, “if it doesn’t benefit all populations.” buff.ly/3GVN4UX #NothingWillStopUs
Looking deeper into mortality rates highlights the importance of eliminating disparities in lung cancer and expanding screening eligibility for at-risk populations. #lcsm #lungcancer Raymond Osarogiagbon, MBBS, FACP Vanderbilt School of Medicine
curetoday.com/view/facing-di…
Tomorrow is the day! 5th International Joint Meeting on Thoracic Surgery is right around the corner!
#jointmeeting2021 #surgery #thoracicsurgery #Barcelona
As an #NOMPartner , I believe it's essential for non-small cell #lungcancer patients to receive biomarker testing to inform treatment. This KNOWvember, spread the word on the importance of #NSCLC patients receiving testing using #KnowYourBiomarker . #NoOneMissed #LCAM
Good news: Modest savings and no evidence for skimping or harm
Disappointing news: Huge investments in care did not lead to notable improvements in quality, patient experiences, or outcomes.
Nice editorial by Raymond Osarogiagbon, MBBS, FACP Samyukta Mullangi Deborah Schrag 9/n
As an #NOMPartner , I'm proud to support LUNGevity Foundation in recognizing KNOWvember as part of #LungCancerAwarenessMonth . It's vital that all non-small cell #lungcancer patients receive comprehensive biomarker testing to inform treatment. *Insert Link* #KnowYourBiomarker #NoOneMissed
#ASCOQLTY21 Great networking breakfast with the inspiring Raymond Osarogiagbon, MBBS, FACP talking about the importance of following your passion, and how to be a vector for change. ASCO #LatinasInMedicine #lcsm